Spatially-resolved tumour infiltrating immune cells and prognosis in breast cancer

Aaron J. Bernstein(National Institutes of Health), Renske Keeman(The Netherlands Cancer Institute), Amber N. Hurson(National Cancer Institute), Fiona M. Blows(University of Cambridge), Manjeet K. Bolla(University of Cambridge), Jodi L. Miller(Alzheimer’s Research UK), Roger L. Milne(The University of Melbourne), Hugo M. Horlings(The Netherlands Cancer Institute), Alexandra J. van den Broek(The Netherlands Cancer Institute), Clara Bodelón(American Cancer Society), James M. Hodge(American Cancer Society), Alpa V Patel(American Cancer Society), Lauren R. Teras(American Cancer Society), Federico Canzian(German Cancer Research Center), Rudolf Kaaks(German Cancer Research Center), Hermann Brenner(German Cancer Research Center), Ben Schoettker(German Cancer Research Center), Sabine Behrens(German Cancer Research Center), Jenny Chang‐Claude(German Cancer Research Center), Tabea Maurer(Universität Hamburg), Nadia Obi(Universität Hamburg), Fergus J. Couch(Mayo Clinic in Arizona), Hasan Ali(University of Cambridge), Carlos Caldas(University of Cambridge), Irene L. Andrulis(Lunenfeld-Tanenbaum Research Institute), Gord Glendon(Lunenfeld-Tanenbaum Research Institute), Anna Marie Mulligan(University Health Network), Wilma E. Mesker(Leiden University Medical Center), Agnes Jager(Erasmus MC Cancer Institute), Annette Heemskerk-Gerritsen(Erasmus MC Cancer Institute), Peter Devilee(Leiden University Medical Center), Scott M. Lawrence(Leidos (United States)), Jolanta Lissowska(Centrum Onkologii), Karun Mutreja(Leidos (United States)), Thomas Ahearn(National Cancer Institute), Stephen Chanock(National Cancer Institute), Máire A. Duggan(University of Calgary), Diana Eccles(University of Southampton), J. Louise Jones(Queen Mary University of London), William Tapper(University of Southampton), Antoinette Hollestelle(Erasmus MC Cancer Institute), Maartje J. Hooning(Erasmus MC Cancer Institute), John W.M. Martens(Erasmus MC Cancer Institute), Carolien H. M. van Deurzen(Erasmus MC Cancer Institute), Angela Cox(University of Sheffield), Simon S. Cross(University of Sheffield), Mikael Hartman(National University of Singapore), Jingmei Li(Agency for Science, Technology and Research), Thomas Choudary Putti(National University of Singapore), Ute Hamann(German Cancer Research Center), Anna Jakubowska(Pomeranian Medical University), Nicki J Camp(University of Utah), Melissa H. Cessna(Intermountain Healthcare), Amy Berrington de González(Institute of Cancer Research), Katarzyna Białkowska(Pomeranian Medical University), Jacek Gronwald(Pomeranian Medical University), Jan Lubi ski(Pomeranian Medical University), Siddhartha Yadav(Mayo Clinic in Arizona), Píetro Lió(University of Cambridge), Doug F. Easton(University of Cambridge), Mustapha Abubakar(National Cancer Institute), Montserrat García‐Closas(Institute of Cancer Research), Paul D.P. Pharoah(Cedars-Sinai Medical Center), Marjanka K. Schmidt(The Netherlands Cancer Institute)
medRxiv
July 22, 2024
Cited by 0Open Access
Full Text

Abstract

Background The immune response in breast tumors has an important role in prognosis, but the role of spatial localization of immune cells and of interaction between subtypes is not well characterized. We evaluated the association between spatially resolved tissue infiltrating immune cells (TIICs) and breast cancer specific survival (BCSS) in a large multicenter study. Patients and methods Tissue microarrays with tumor cores from 17,265 breast cancer patients of European descent were stained for CD8, FOXP3, CD20, and CD163. We developed a machine learning based tissue segmentation and immune cell detection algorithm using Halo to score each image for the percentage of marker positive cells by compartment (overall, stroma, or tumor). We assessed the association between log transformed TIIC scores and BCSS using Cox regression. Results Total CD8+ and CD20+ TIICs (stromal and intra-tumoral) were associated with better BCSS in women with ER-negative (HR per standard deviation = 0.91 [95% CI 0.85 - 0.98] and 0.89 [0.84 - 0.94] respectively) and ER-positive disease (HR = 0.92 [95% CI 0.87 - 0.98] and 0.93 [0.86 - 0.99] respectively) in multi-marker models. In contrast, CD163+ macrophages were associated with better BCSS in ER-negative disease (0.94 [0.87 - 1.00]) and a poorer BCSS in ER-positive disease 1.04 [0.99 - 1.10]. There was no association between FOXP3 and BCSS. The observed associations tended to be stronger for intra-tumoral than stromal compartments for all markers. However, the TIIC markers account for only 7.6 percent of the variation in BCSS explained by the multi-marker fully-adjusted model for ER-negative cases and 3.0 percent for ER-positive cases. Conclusions The presence of intra-tumoral and stromal TIICs is associated with better BCSS in both ER-negative and ER-positive breast cancer. This may have implications for the use of immunotherapy. However, the addition of TIICs to existing prognostic models would only result in a small improvement in model performance.


Related Papers

No related papers found

Powered by citation graph analysis